Matthew Ros

Insider Reports History

Entity
Individual
Location
C/O Epizyme, Inc., 400 Technology Square, Cambridge, MA
Signature
/s/ Evan D. Kearns, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Matthew Ros:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Epizyme, Inc. Executive Vice President, Chief Strategy & Business Officer Common Stock, par value $0.0001 111K $157K $1.41 Aug 16, 2021 Direct
Epizyme, Inc. Executive Vice President, Chief Strategy & Business Officer Stock Option (Right to Buy) 134K Aug 16, 2021 Direct
Cogent Biosciences, Inc. Director Stock Option (Right to Buy) 44.7K Jun 5, 2024 Direct

Insider Reports Filed by Matthew Ros

Symbol Company Period Transactions Value $ Form Type Date Filed Role
COGT Cogent Biosciences, Inc. Jun 5, 2024 1 $0 4 Jun 13, 2024 Director
COGT Cogent Biosciences, Inc. Jan 2, 2024 1 $0 4 Jan 4, 2024 Director
COGT Cogent Biosciences, Inc. Oct 2, 2023 1 $0 4 Oct 3, 2023 Director
COGT Cogent Biosciences, Inc. Jul 3, 2023 1 $0 4 Jul 5, 2023 Director
COGT Cogent Biosciences, Inc. Jun 7, 2023 1 $0 4 Jun 8, 2023 Director
COGT Cogent Biosciences, Inc. Apr 3, 2023 1 $0 4 Apr 4, 2023 Director
COGT Cogent Biosciences, Inc. Jan 3, 2023 1 $12.9K 4 Jan 4, 2023 Director
COGT Cogent Biosciences, Inc. Oct 3, 2022 1 $12.9K 4 Oct 4, 2022 Director
COGT Cogent Biosciences, Inc. Jul 1, 2022 1 $12.9K 4 Jul 5, 2022 Director
COGT Cogent Biosciences, Inc. Jun 7, 2022 1 $0 4 Jun 9, 2022 Director
COGT Cogent Biosciences, Inc. Apr 1, 2022 1 $12.9K 4 Apr 5, 2022 Director
COGT Cogent Biosciences, Inc. Jan 3, 2022 1 $11.6K 4 Jan 4, 2022 Director
COGT Cogent Biosciences, Inc. Oct 1, 2021 1 $12.4K 4 Oct 5, 2021 Director
EPZM Epizyme, Inc. Aug 16, 2021 2 $0 4 Aug 18, 2021 Executive Vice President, Chief Strategy & Business Officer
COGT Cogent Biosciences, Inc. Jul 1, 2021 1 $10.6K 4 Jul 6, 2021 Director